RainSure Scientific Company Profile

Background

Founded in 2017, RainSure Scientific is an innovative biotechnology company specializing in advancements in microfluidics, engineering, and molecular biology. The company's mission is to advance diagnostic and life science solutions with passion and perseverance, aiming to provide innovative, high-quality, and high-performance products to meet the unmet needs of life science research and clinical diagnostics.

Key Strategic Focus

RainSure Scientific focuses on developing cutting-edge microfluidic technologies, advanced optical platforms, and intelligent software systems to create internationally leading molecular diagnostic platforms. The company's product portfolio includes digital PCR systems, real-time PCR systems, and in vitro diagnostic reagents, targeting applications such as tumor liquid biopsy, pathogen detection, and drug resistance gene detection.

Financials and Funding

RainSure Scientific has successfully completed multiple funding rounds:

• Seed Round (November 2017): Raised $1.36 million.

• Early Stage VC (July 2018): Raised $1.97 million, bringing the total to $3.33 million.

• Series A (September 2019): Amount undisclosed.

• Series B1 (February 2021): Raised tens of millions of yuan, led by Zero2IPO Asset Management, with participation from Kaitai Capital, Future Capital, and Volcanics Venture.

• Series C1 (November 2022): Amount undisclosed.

The funds have been allocated towards R&D, GMP-compliant manufacturing facility construction, optimization of domestic sales teams, and expansion of overseas sales channels.

Pipeline Development

RainSure Scientific has developed and launched several key products:

• RS32 Digital PCR System: An all-in-one system integrating droplet generation, PCR thermal cycling, and fluorescence signal analysis, capable of detecting up to 100 targets in a single reaction.

• DropDx Digital PCR System: A second-generation digital PCR system suitable for various applications, including tumor biomarker research and viral pathogen detection.

• FastPlex™ Sepsis Ultra-Multiplexing Assay: A digital PCR test detecting and quantifying up to 31 pathogens and 9 antibiotic-resistant genes directly from patient whole blood samples without blood culture in 5 hours.

• Fast-16 Real-Time PCR System: A portable real-time fluorescence quantitative PCR system accommodating up to 6 fluorescence detection channels with a standard detection capacity of 16 wells.

Technological Platform and Innovation

RainSure Scientific's technological innovations include:

• Droplet Fluorescent Barcoding Technology: Enables ultra-multiplexed assay detection, identifying up to 100 targets in a single reaction.

• Microfluidic Technologies: Facilitate precise control and manipulation of fluids at the microscale, enhancing the efficiency and accuracy of molecular diagnostics.

• Advanced Optical Platforms: Improve the sensitivity and specificity of detection systems, crucial for applications like digital PCR.

Leadership Team

The management team comprises PhDs from prestigious institutions such as Brown University, Carnegie Mellon University, Stanford University, Cornell University, and Caltech.

• Yaqi Wang, Ph.D.: Chairman, Founder & Chief Executive Officer.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within the company's leadership team.

Competitor Profile

Market Insights and Dynamics

The digital PCR market is rapidly evolving, driven by technological advancements and increasing research applications. Key players shaping this landscape include:

• Bio-Rad Laboratories: Offers a broad range of dPCR solutions known for high sensitivity and precision.

• Thermo Fisher Scientific: Provides cutting-edge dPCR reagents and consumables, focusing on enhancing assay performance and reliability.

• Stilla Technologies: Known for innovative dPCR platforms and consumables, offering solutions that improve assay precision.

• Standard BioTools: Offers high-quality dPCR reagents catering to both research and clinical applications.

• Qiagen: Renowned for exceptional performance and consistency in dPCR reagents and consumables.

• BioTNS: Specializes in advanced dPCR reagents and consumables, contributing to the growing demand for precision molecular diagnostics.

Competitor Analysis

RainSure Scientific differentiates itself through its proprietary technologies, such as droplet fluorescent barcoding and advanced microfluidic systems, enabling ultra-multiplexed assay detection and high-throughput capabilities. The company's focus on integrating multiple functions into single platforms, like the RS32 Digital PCR System, provides a competitive edge in terms of efficiency and ease of use.

Strategic Collaborations and Partnerships

RainSure Scientific has established strategic distribution and business partnerships in Europe, Southeast Asia, the United States, and China, strengthening its market position and expanding its global reach.

Operational Insights

The company's strategic considerations include:

• Product Innovation: Continuous development of cutting-edge technologies to maintain a competitive edge.

• Global Expansion: Establishing and strengthening partnerships to enhance market presence worldwide.

• Quality Assurance: Building GMP-compliant manufacturing facilities to ensure product quality and regulatory compliance.

Strategic Opportunities and Future Directions

RainSure Scientific's strategic roadmap includes:

• Expansion of Product Portfolio: Developing new diagnostic tools and assays to address emerging healthcare challenges.

• Market Penetration: Increasing presence in existing markets and entering new regions through strategic partnerships.

• Technological Advancements: Investing in R&D to enhance existing technologies and develop innovative solutions.

Contact Information

For more information, visit RainSure Scientific's official website.